Form 8-K

8-K — Lifeward Ltd.

Accession: 0001178913-26-004140

Filed: 2026-08-14

Period: 2026-08-10

CIK: 0001607962

SIC: 3842 (ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUPPLIES)

Item: Results of Operations and Financial Condition

Item: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Item: Financial Statements and Exhibits

Documents

8-K — zk2635970.htm (Primary)

EX-99.1 — EXHIBIT 99.1 (exhibit_99-1.htm)

GRAPHIC (image00002.jpg)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K

8-K (Primary)

Filename: zk2635970.htm · Sequence: 1

false000160796200-0000000NASDAQ00016079622026-08-102026-08-10

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 10, 2026

Lifeward Ltd.

(Exact name of registrant as specified in its charter)

Israel

001-36612

Not applicable

(State or Other Jurisdiction of Incorporation)

(Commission File Number)

(IRS Employer Identification No.)

2 Cabot Rd., Hudson, MA

01749

(Address of principal executive offices)

(Zip Code)

Registrant’s telephone number, including area code: +508.251.1154

Not applicable

(Former name or former address, if changed since last report)

Securities registered pursuant to

Section 12(b) of the Exchange Act

Trading Symbol

Name of each exchange on which registered

Ordinary shares, no par value

LFWD

Nasdaq Capital Market

Check the appropriate box below if the Form 8-K

filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐

Written communications pursuant to Rule 425 under the

Securities Act (17 CFR 230.425)

☐

Soliciting material pursuant to Rule 14a-12 under the

Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement communications pursuant to Rule

14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement communications pursuant to Rule

13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933

(§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for

complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition.

On August 14, 2026, Lifeward Ltd. (the “Company”) issued a press release announcing its financial results for the second quarter

ended June 30, 2026. A copy of the press release is being furnished herewith as Exhibit 99.1.

The information furnished pursuant to this Item 2.02, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18

of the Securities Exchange Act of 1934, as amended (the “1934 Act”), nor shall it be deemed “incorporated by reference” into any filing under the Securities Act of 1933, as amended, or the 1934 Act, except as may be expressly set forth by

specific reference in such filing.

Item 5.02

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officer.

Resignation of Directors

On August 12, 2026, each of Robert J. Marshall, Jr., Michael Swinford and William Mark Sigsbee notified the Board of their decision

to step down from the Board, effective as of August 13, 2026. The departure of each of Messrs. Marshall, Swinford and Sigsbee did not result from any disagreement with the Company on any matter relating to its operations, policies or practices.

The Company extends its deepest gratitude to each of Messrs. Marshall, Swinford and Sigsbee for their distinguished service to the Board and lasting contributions to the Company.

Departure of Chief Financial Officer

On August 14, 2026, the Company announced that Almog Adar will step down as the Chief Financial Officer of the Company. Mr. Adar

will continue to serve in his existing role through September 30, 2026 to assist with a transition to a successor. For purposes of the separation benefits under his existing employment agreement, as amended, Mr. Adar’s departure will be treated

as a termination without cause. On August 10, 2026, the Company entered into a separation agreement with Mr. Adar providing for separation benefits substantially similar to those contemplated by Mr. Adar’s existing employment agreement. A copy of

Mr. Adar’s separation agreement will be filed as an exhibit to the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2026.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

99.1

Press release dated August 14, 2026 of Lifeward Ltd., announcing financial results for the second

quarter ended June 30, 2026.*

104

Cover Page Interactive Data File (embedded within the Inline XBRL document).

Furnished herewith

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be

signed on its behalf by the undersigned hereunto duly authorized.

Lifeward Ltd.

Dated: August 14, 2026

By:

/s/ Almog Adar

Name:

Almog Adar

Title:

Chief Financial Officer

EX-99.1 — EXHIBIT 99.1

EX-99.1

Filename: exhibit_99-1.htm · Sequence: 2

Exhibit 99.1

Lifeward Reports Strong Second Quarter 2026 Financial Results as

Commercial Execution Drives Growth

Revenue increase and operating performance improve as capital-efficient distribution strategy gains

momentum

Strengthened balance sheet and expanding rehabilitation platform support continued commercial

execution

HUDSON, MA, and YOKNEAM ILLIT, Israel, August 14, 2026 – Lifeward Ltd. (Nasdaq: LFWD) (“Lifeward” or the “Company”), a diversified biomedical innovation company with a portfolio of

commercialized neurorehabilitation products and a biomedical pipeline, today reported financial results for the second quarter ended June 30, 2026.

Corporate & Financial Highlights

•

Revenue increased 16% to $6.6 million in the second quarter of 2026 compared to the second quarter of 2025, marking the strongest quarterly revenue performance since the fourth quarter of 2024. The

increase reflects continued execution of Lifeward's commercial strategy and growing adoption across the Company's rehabilitation portfolio.

•

Strengthened the Company's balance sheet to a proforma cash balance of approximately $11 million. The Company had a cash balance of $9.4 million as of June 30,

2026. Through a strategic financing closed on July 6, 2026, providing up to $11.2 million in growth capital, Lifeward raised approximately $5.6 million, $4.1 million of which was received during the second quarter, and $1.5 million was

received in July. An additional approximately $5.6 million is available upon achieving either a 150% increase in ReWalk sales or the Company's common stock trading at $13.80 or higher for ten consecutive trading days.

•

Continued successful execution of Lifeward's capital-efficient distribution strategy, expanding patient access through established rehabilitation and durable medical equipment distribution partners

while building scalable commercial infrastructure designed to support portfolio growth. In August 2026, Lifeward launched a pilot program with Ottobock Care, a leading U.S. mobility technology patient care organization with more than 50

patient clinics nationwide, broadening access to ReWalk Personal Exoskeleton across the country.

•

Further strengthened Lifeward's restorative healthcare platform, with ongoing investigational device development, combining market-leading rehabilitation technologies with an established

reimbursement infrastructure.

•

Advanced the ORMD-0801 oral insulin clinical program, with preparations ongoing for the planned Phase 2 U.S. clinical trial. Clinical development activities continue to be managed by Oramed under the

strategic collaboration utilizing funds from the Oratech acquisition.

•

Board composition. Effective August 13, 2026, the Company’s Chairman of the Board Bob Marshall and Directors Mike Swinford and William Sigsbee have decided to step down from the board. The Company

extends its gratitude to each of Messrs. Marshall, Swinford and Sigsbee for their service and lasting contributions to the Company.

•

Executive transition. The Company’s Chief Financial Officer, Almog Adar, has decided to depart the Company effective September 30, 2026, and will assist with a transition period to his successor. The

Company extends its gratitude to Mr. Adar for his service and lasting contributions to the Company.

"The second quarter marks another important milestone in Lifeward's transformation into a scaled restorative healthcare company, with revenue growth demonstrating that the strategy we have

implemented is working,” said Mark Grant, President and Chief Executive Officer of Lifeward. “Backed by a strong sales pipeline, we expect this revenue momentum to continue in the second half of 2026.”

"Over the past year, we have strengthened Lifeward’s restorative healthcare platform, which includes multiple commercial products, a strong reimbursement infrastructure, a scalable capital-efficient

distribution model and an exciting pipeline of potential future rehabilitation technologies. These capabilities create a powerful foundation that we believe will support sustainable long-term growth and expand access to life-changing technologies for

patients around the world."

"As part of the governance changes announced today, I am proud of what our team has accomplished together with the support and guidance of our board. We have established the strategy, strengthened

the balance sheet, built the commercial infrastructure and positioned the Company to capitalize on significant opportunities ahead."

Second Quarter 2026 Financial Results

Revenue increased 16% to $6.6 million in the second quarter of 2026, compared to $5.7 million in the second quarter of 2025. The $0.9 million increase was driven by a 13% increase in ReWalk Personal

exoskeletons sales to $2.5 million in the second quarter of 2026 compared to the same period in 2025, primarily reflecting stronger sales in Europe, and AlterG products and services which increased 25% to $4.1 million from the same period in 2025,

primarily reflecting higher U.S. unit shipments, service revenue and average selling prices. MyoCycle FES bike sales were $0.1 million, unchanged from the second quarter of 2025.

Gross margin was 41% during the second quarter of 2026, compared to 44% in the second quarter of 2025. The year-over-year decrease was primarily due to higher tariffs, fluctuations in foreign

exchange rates, and a 4% revenue sharing expense associated with the Oramed transaction.

Total operating expenses in the second quarter of 2026 declined 24% to $6.9 million, compared to $9.1 million in the second quarter of 2025, primarily due to $2.8 million of one-time impairment

charges recorded in the prior-year period. Excluding these charges, the year-over-year increase primarily reflected higher research and development expenses, including $0.7 million in Oratech clinical trial costs, partially offset by lower sales and

marketing and general and administrative expenses. On a non-GAAP basis, which excludes the items listed in the attached non-GAAP reconciliation table, adjusted operating expenses increased by 8% to $6.5 million in the second quarter of 2026, compared

to $6.0 million in the second quarter of 2025, with the year-over-year change primarily attributable to $0.7 million in Oratech clinical trial costs.

Operating loss declined by 37% in the second quarter of 2026 to $4.2 million, compared to $6.6 million in the second quarter of 2025, primarily due to $2.8 million of impairment charges recorded in

the second quarter of 2025 and lower sales and marketing and general and administrative expenses, partially offset by $0.7 million in Oratech clinical trial costs in the second quarter of 2026. On a non-GAAP basis, which excludes the items in the

attached non-GAAP reconciliation table, adjusted operating loss was $3.8 million in the second quarter of 2026, compared to $3.5 million in the second quarter of 2025, with the year-over-year change primarily attributable to $0.7 million in Oratech

clinical trial costs, partially offset by continued operating efficiencies, particularly in sales and marketing and general and administrative expenses.

Net loss was $11.5 million, or $4.12 per share, in the second quarter of 2026, compared to $6.6 million, or $7.01 per share, in the second quarter of 2025. Net loss increased by $4.9 million

primarily due to non-cash fair value charges in warrant and derivative liabilities, compared to the three months ended June 30, 2025. On a non-GAAP basis, which excludes the items in the attached non-GAAP reconciliation table, adjusted net loss was

$4.1 million in the second quarter of 2026, compared to $3.5 million in the second quarter of 2025, with the year-over-year change primarily attributable to $0.7 million in Oratech clinical trial costs.

Liquidity

As of June 30, 2026, Lifeward had $9.4 million in unrestricted cash and cash equivalents, compared to $2.2 million as of December 31, 2025. The proforma cash balance is approximately $11 million,

inclusive of $1.5 million in proceeds from the July 6, 2026 capital raise of $5.6 million, $4.1 million of which was received prior to June 30, 2026.

About Lifeward

Lifeward is a global innovator focused on advancing medical technologies and biomedical solutions that improve lives. The Company’s established portfolio includes market-leading neurorehabilitation

technologies such as the ReWalk® Exoskeleton, AlterG® Anti-Gravity system, MyoCycle® FES System, and ReStore® Exo-Suit. These solutions span the continuum of care in physical rehabilitation and recovery, deploying the most advanced robotics and AI

technologies to restore full health and quality of life to a broadening patient population. The Company is now executing a strategic evolution into a diversified biomedical company, expanding beyond rehabilitation and into high-value therapeutic

platforms. This includes its Protein Oral Delivery (POD™) platform, designed to enable oral delivery of biologic drugs, with lead candidate ORMD-0801 (oral insulin) targeting a large and underserved diabetes market.

Lifeward has operations in the United States, Israel, and Germany. For more information on the Lifeward mission and product portfolio, please visit GoLifeward.com.

Lifeward®, ReWalk®, ReStore® and Alter G® are registered trademarks of Lifeward Ltd. and/or its affiliates.

Forward-Looking Statements

In addition to historical information, this press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, Section 27A of

the U.S. Securities Act of 1933, and Section 21E of the U.S. Securities Exchange Act of 1934. Such forward-looking statements may include projections regarding the Company's future performance and other statements that are not statements of

historical fact and, in some cases, may be identified by words like "anticipate," "assume," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "future," "will," "should," "would," "seek"

and similar terms or phrases. The forward-looking statements contained in this press release are based on management's current expectations, which are subject to uncertainty, risks and changes in circumstances that are difficult to predict and many

of which are outside of the Company’s control. Important factors that could cause the Company’s actual results to differ materially from those indicated in the forward-looking statements include, among others: management’s expectations, hopes,

beliefs, intentions or strategies regarding the future including, without limitation, statements regarding: the future operations of Lifeward, including research and development activities; the nature, strategy and focus of Lifeward; Lifeward’s

ability to successfully integrate Oratech Pharmaceuticals Ltd. into its organization and realize the anticipated benefits therefrom; anticipated clinical drug development activities and related timelines, and other clinical results; the sufficiency

of post-transaction resources to support the advancement of Lifeward’s pipeline through certain milestones and the time period over which Lifeward’s post-transaction capital resources will be sufficient to fund its anticipated operations; unexpected

costs, charges or expenses resulting from the strategic transaction; expected timing and results of the ORMD-0801 clinical trial; legislative, regulatory, political and economic developments; the acceptance of the ReWalk 7 Personal Exoskeleton by

healthcare professionals and patients; uncertainties associated with future clinical trials and the clinical development process, the product development process and FDA regulatory submission review and approval process; the Company's ability to have

sufficient funds to meet certain future capital requirements, which could impair the Company's efforts to develop and commercialize existing and new products; the Company's ability to maintain and grow its reputation and the market acceptance of its

products; the Company's ability to achieve reimbursement from third-party payors, including CMS, for its products; the Company's limited operating history and its ability to leverage its sales, marketing and training infrastructure; the Company's

expectations as to its clinical research program and clinical results; the Company's expectations regarding future growth, including its ability to increase sales in its existing geographic markets and expand to new markets; the Company’s ability to

continue to operate as a going concern; the Company's ability to obtain certain components of its products from third-party suppliers and its continued access to its product manufacturers; the Company’s ability to navigate any difficulties associated

with moving production of its AlterG Anti-Gravity Systems to a contract manufacturer and transitioning the manufacturing of its ReWalk products to its in-house manufacturer; the Company's ability to improve its products and develop new products; the

Company's compliance with medical device reporting regulations to report adverse events involving the Company's products, which could result in voluntary corrective actions or enforcement actions such as mandatory recalls, and the potential impact of

such adverse events on the Company's ability to market and sell its products; the Company's ability to gain and maintain regulatory approvals; the Company's ability to maintain adequate protection of its intellectual property and to avoid violation

of the intellectual property rights of others; the risk of a cybersecurity attack or breach of the Company's IT systems significantly disrupting its business operations; the ability of a refreshed Board of Directors to effectively oversee and manage

the Company and execute its strategy; the Company's ability to use effectively the proceeds of its offerings of securities; and other factors discussed under the heading "Risk Factors" in the Company’s annual report on Form 10-K, as amended, for the

year ended December 31, 2025 filed with the SEC and other documents subsequently filed with or furnished to the SEC. Any forward-looking statement made in this press release speaks only as of the date hereof. Factors or events that could cause the

Company’s actual results to differ from the statements contained herein may emerge from time to time, and it is not possible for the Company to predict all of them. Except as required by law, the Company undertakes no obligation to publicly update

any forward-looking statements, whether as a result of new information, future developments or otherwise.

Contact:

Almog Adar

Chief Financial Officer

Lifeward

E: media@golifeward.com

E: ir@golifeward.com

Lifeward Ltd. And subsidiaries

Condensed Consolidated Statements of Operations

(Unaudited)

(In thousands, except share and per share data)

Three Months Ended

Six Months Ended

June 30,

2026

2025

2026

2025

Revenue

6,623

5,724

10,546

10,758

Cost of revenues

3,914

3,213

6,495

6,125

Gross profit

2,709

2,511

4,051

4,633

Operating expenses:

Research and development, net

1,754

767

7,599

1,685

Sales and marketing

3,531

3,785

6,802

7,622

General and administrative

1,576

1,739

4,141

3,959

Impairment charges

2,783

Total operating expenses

6,861

9,074

18,542

16,049

Operating loss

(4,152

)

(6,563

)

(14,491

)

(11,416

)

Financial expense (income), net

7,357

)

7,805

(31

)

Loss before income taxes

(11,509

)

(6,562

)

(22,296

)

(11,385

)

Taxes on income

Net loss

(11,519

)

(6,562

)

(22,312

)

(11,396

)

Basic net loss per ordinary share

(4.12

)

(7.01

)

(10.09

)

12.59

Weighted average number of shares used in computing net loss per ordinary share basic and diluted (*)

2,796,621

935,785

2,210,280

904,881

(*) All share and per share amounts presented in this note have been retroactively adjusted to reflect the Company’s 1-for-12 reverse share split effected on February 24, 2026.

Lifeward Ltd. And subsidiaries

Condensed Consolidated Balance Sheets

(In thousands)

(Unaudited)

(Audited)

June 30,

December 31,

2026

2025

Assets

Current assets

Cash and cash equivalents

9,448

2,169

Restricted Cash

240

Clinical trial services asset

504

Trade receivables, net of credit losses of $212 and $192, respectively

7,861

6,138

Prepaid expenses and other current assets

1,979

1,528

Inventories

6,151

5,732

Total current assets

25,947

15,807

Restricted cash and other long term assets

488

209

Clinical trial services asset

378

Operating lease right-of-use assets

2,473

1,544

Property and equipment, net

527

585

Intangible Assets

432

Goodwill

4,755

Total assets

35,000

22,900

Liabilities and equity

Current liabilities

Trade payables

6,135

5,590

Current maturities of operating leases

743

425

Convertible promissory note

2,803

Other current liabilities

4,281

3,221

Total current liabilities

11,159

12,039

Non-current operating leases

1,813

1,159

Convertible promissory notes, net

4,432

Financing liabilities

4,083

Other long-term liabilities

1,297

1,294

Shareholders’ equity

12,216

8,408

Total liabilities and equity

35,000

22,900

Lifeward Ltd. And subsidiaries

Condensed Consolidated Statements of Cash Flows

(Unaudited)

(In thousands)

Six Months Ended

June 30,

2026

2025

Net cash used in operating activities

(9,680

)

(9,429

)

Net cash provided by (used in) investing activities

6,472

)

Net cash provided by financing activities

10,505

7,779

Effect of Exchange rate changes on cash, cash equivalents and restricted cash

Increase (decrease) in cash, cash equivalents, and restricted cash

7,309

(1,585

)

Cash, cash equivalents, and restricted cash at beginning of period

2,579

7,108

Cash, cash equivalents, and restricted cash at end of period

9,888

5,523

Lifeward Ltd. And subsidiaries

(Unaudited)

(In thousand)

Three Months Ended

Six Months Ended

June 30,

2026

2025

2026

2025

Revenues based on customer’s location:

United States

4,063

3,062

6,424

6,271

Europe

1,053

693

1,757

1,473

Germany

1,134

1,410

1,831

1,966

Asia - Pacific

235

124

287

166

Rest of the world

138

435

247

882

Total Revenues

6,623

5,724

10,546

10,758

Three Months Ended

Six Months Ended

June 30,

Dollars in thousands, except per share data

2026

2025

2026

2025

GAAP net loss

(11,519

)

(6,562

)

(22,312

)

(11,396

)

Adjustments:

Amortization of intangible assets

Non-cash acquired in-process R&D expense

4,947

Oramed transaction-related expenses

619

Other income related to the settlement of the post closing statement for the acquisition of AlterG

(142

)

(142

)

Restructuring

244

700

244

700

Remeasurement of earnout liability

(608

)

(608

)

Impairment charges

2,783

Stock-based compensation expenses

262

182

439

402

Non-cash amortization of debt discount associated with the convertible notes and warrants

153

958

Fair value remeasurement of warrant and derivative liabilities

6,912

6,387

Non-GAAP net loss

(4,080

)

(3,505

)

(8,850

)

(8,119

)

Weighted average shares used in computing net loss per share (*)

2,796,621

935,785

2,210,280

904,881

Non-GAAP net loss per share

(1.46

)

(3.75

)

(4.00

)

(8.97

)

(*) All share and per share amounts presented in this note have been retroactively adjusted to reflect the Company’s 1-for-12 reverse share split effected on February 24, 2026.

Three Months Ended

Six Months Ended

June 30,

2026

2025

2026

2025

Dollars in thousands

% of revenue

GAAP operating loss

(4,152

)

(62.7

(6,563

)

(114.7

(14,491

)

(137.4

(11,416

)

(106.1

Amortization of intangible assets

0.2

0.1

Non-cash acquired in-process R&D expense

4,947

46.9

Oramed transaction-related expenses

619

5.9

Other income related to the settlement of the post closing statement for the acquisition of AlterG

(142

)

(2.1

(142

)

(1.3

Restructuring

244

3.7

700

12.2

244

2.3

700

6.5

Remeasurement of earnout liability

(608

)

(10.6

(608

)

(5.7

Impairment charges

2,783

48.6

2,783

25.9

Stock-based compensation expenses

262

4.0

182

3.2

439

4.2

402

3.7

Non-GAAP operating loss

(3,778

)

(56.9

(3,506

)

(61.3

(8,374

)

(79.3

(8,139

)

(75.7

Three Months Ended

Six Months Ended

June 30,

2026

2025

2026

2025

Dollars in thousands

% of revenue

GAAP gross profit

2,709

40.9

2,511

43.9

4,051

38.4

4,633

43.1

Adjustments:

Stock-based compensation expenses

0.1

Non-GAAP gross profit

2,710

40.9

2,515

44.0

4,057

38.5

4,640

43.2

Three Months Ended

Six Months Ended

June 30,

2026

2025

2026

2025

Dollars in thousands

% of revenue

GAAP research & development

1,754

26.5

767

13.4

7,599

72.1

1,685

15.7

Adjustments:

Amortization of intangible assets

(10

)

(0.2

(10

)

(0.1

Non-cash acquired in-process R&D expense

(4,947

)

(46.9

Stock-based compensation expenses

(37

)

(0.6

(37

)

(0.6

(74

)

(0.7

(73

)

(0.7

Non-GAAP research & development

1,707

25.7

730

12.8

2,568

24.4

1,612

15.0

Three Months Ended

Six Months Ended

June 30,

2026

2025

2026

2025

Dollars in thousands

% of revenue

GAAP sales & marketing

3,531

53.3

3,785

66.1

6,802

64.5

7,622

70.8

Adjustments:

Restructuring

(244

)

(3.7

(277

)

(4.8

(244

)

(2.3

(277

)

(2.6

Stock-based compensation expenses

)

(0.1

(56

)

(1.0

(63

)

(0.6

(138

)

(1.3

Non-GAAP sales & marketing

3,282

49.5

3,452

60.3

6,495

61.6

7,207

66.9

Three Months Ended

Six Months Ended

June 30,

2026

2025

2026

2025

Dollars in thousands

% of revenue

GAAP general & administrative

1,576

23.8

1,739

30.4

4,141

39.3

3,959

36.8

Adjustments:

Other income related to the settlement of the post closing statement for the acquisition of AlterG

142

2.1

142

1.3

Oramed transaction-related expenses

(619

)

(5.9

Restructuring

(423

)

(7.4

(423

)

(3.9

Remeasurement of earnout liability

608

10.6

608

5.7

Stock-based compensation expenses

(219

)

(3.3

(85

)

(1.5

(296

)

(2.8

(184

)

(1.7

Non-GAAP general & administrative

1,499

22.6

1,839

32.1

3,368

31.9

3,960

36.9

GRAPHIC

Filename: image00002.jpg · Sequence: 6

Binary file (4146 bytes)

Download image00002.jpg

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 8

v3.26.1

Document and Entity Information

Aug. 10, 2026

Cover [Abstract]

Document Type

8-K

Amendment Flag

false

Document Period End Date

Aug. 10, 2026

Entity File Number

001-36612

Entity Registrant Name

Lifeward Ltd.

Entity Central Index Key

0001607962

Entity Incorporation, State or Country Code

Entity Tax Identification Number

00-0000000

Entity Address, Address Line One

2 Cabot Rd.

Entity Address, City or Town

Hudson

Entity Address, Country

Entity Address, Postal Zip Code

01749

City Area Code

508

Local Phone Number

251.1154

Title of 12(b) Security

Ordinary shares, no par value

Trading Symbol

LFWD

Security Exchange Name

NASDAQ

Entity Emerging Growth Company

false

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

ISO 3166-1 alpha-2 country code.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCountry

Namespace Prefix:

dei_

Data Type:

dei:countryCodeItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration